by Ioannis Zabetakis
A very interesting and rather intriguing paper on omega-3 fatty acids and fish was published last May in Clinical Nutrition: the authors have reviewed literature with regard to the supplementation of omega-3 LC-PUFAs
Previous evidence stated that high doses omega-3 LC-PUFAs produce a small but significant decrease in blood pressure in older and hypertensive subjects.
Due to the increasing interest in the benefits of LC-PUFAs, the authors aimed to evaluate the scientific evidence provided in the past five years (2012–2016) on the effects of the intake of omega-3 LC-PUFAs on cardiovascular risk factors such as inflammation and oxidative stress, through a systematic review in PubMed database.
28 articles were related to cardiovascular disease (CVD) and are included in this systematic review. The studies included healthy subjects and CVD patients; we included the number of subjects, type of study, type and doses of omega-3 LC-PUFAs, primary outcomes, and results.
The use of omega-3 LC-PUFAs for ameliorating CVD risk factors can be recommended. However, the administration of omega-3 does not seem to show any benefit for the management of CVD or associated complications (Rangel-Huerta and Gil).
However, the devil is always hidden in the tiny details. Having a closer look at this paper and especially table 3, it can be seen that the authors compare head-to-head studies where pure omega-3 fatty acids were supplemented to humans to studies where fish was consumed.
Despite the fact, that this comparison is not unusual in literature; we have some scientific concerns whether this is the right way of evaluating the cardioprotective properties of fish.
A very interesting and rather intriguing paper on omega-3 fatty acids and fish was published last May in Clinical Nutrition: the authors have reviewed literature with regard to the supplementation of omega-3 LC-PUFAs
 |
| Ioannis Zabetakis |
Previous evidence stated that high doses omega-3 LC-PUFAs produce a small but significant decrease in blood pressure in older and hypertensive subjects.
Due to the increasing interest in the benefits of LC-PUFAs, the authors aimed to evaluate the scientific evidence provided in the past five years (2012–2016) on the effects of the intake of omega-3 LC-PUFAs on cardiovascular risk factors such as inflammation and oxidative stress, through a systematic review in PubMed database.
28 articles were related to cardiovascular disease (CVD) and are included in this systematic review. The studies included healthy subjects and CVD patients; we included the number of subjects, type of study, type and doses of omega-3 LC-PUFAs, primary outcomes, and results.
The use of omega-3 LC-PUFAs for ameliorating CVD risk factors can be recommended. However, the administration of omega-3 does not seem to show any benefit for the management of CVD or associated complications (Rangel-Huerta and Gil).
However, the devil is always hidden in the tiny details. Having a closer look at this paper and especially table 3, it can be seen that the authors compare head-to-head studies where pure omega-3 fatty acids were supplemented to humans to studies where fish was consumed.
Despite the fact, that this comparison is not unusual in literature; we have some scientific concerns whether this is the right way of evaluating the cardioprotective properties of fish.
Read the full article, HERE.
The Aquaculturists
This blog is maintained by The Aquaculturists staff and is supported by the
magazine International Aquafeed which is published by Perendale Publishers Ltd
For additional daily news from aquaculture around the world: aquaculture-news
No comments:
Post a Comment